Sentiment Analysis: Increasing Medical Marijuana and Cannabidiol Research

Executive Order: 14370

Issued: December 18, 2025

Federal Register Doc. No.: 2025-23846

1) OVERALL TONE & SHIFTS‌‍⁠

The‌‍⁠ order opens with a patient-centered, reform-oriented tone, framing decades of federal marijuana scheduling policy as a failure to serve Americans—particularly veterans, seniors, and chronic pain sufferers. The language is notably data-heavy for an executive order, marshaling statistics from FDA reviews, HHS recommendations, and patient surveys to build an evidence-based case for policy change.

The tone shifts across sections: Section 1 is diagnostic and mildly critical of prior federal inaction; Section 2 becomes directive and procedural, issuing specific agency mandates; Section 3 closes with standard boilerplate legal language that is neutral and administrative. The overall register is reformist but measured—the order frames rescheduling not as a radical departure but as a logical extension of existing agency recommendations already in progress. Notably, the order is not simply pro-access in its orientation; it is also materially precautionary, explicitly flagging long-term health risks in vulnerable populations alongside its reform goals.

2) SENTIMENT CATEGORIES‌‍⁠

Positive sentiments (as the order frames them)

The order states that rescheduling marijuana to Schedule III would align federal policy with the medical reality experienced by millions of patients and thousands of licensed practitioners
The order frames increased research infrastructure as a benefit that will "better serve Americans," particularly vulnerable populations
The order states that hemp-derived CBD products "have shown potential to improve patient symptoms for common ailments," presenting them as potentially beneficial while simultaneously noting significant safety concerns
The order states that veterans using medical marijuana reported reduced opioid use, framing this as a meaningful public health benefit
The order frames expedited completion of the rescheduling rulemaking as a positive step, and separately frames increased research as the mechanism for closing the gap between current medical marijuana and CBD use and medical knowledge of risks and benefits

Negative sentiments (as the order describes them)

The order states that "decades of Federal drug control policy have neglected marijuana's medical uses," characterizing prior federal scheduling as an oversight with real human costs
The order frames the current Schedule I classification as having "impeded research," leaving patients and doctors without adequate guidance
The order describes the current legal landscape as leaving Americans "without adequate guidance or product safeguards for CBD"
The order claims that inaccurate labeling of commercially available CBD products "pos[es] safety risks for consumers"
The order states that low rates of patient-provider communication about marijuana use—56 percent among older Americans—place seniors "at increased risk of drug interactions or other adverse events"
The order characterizes the federal delay in recognizing medical marijuana's uses as not serving Americans who report health benefits
The order explicitly flags the need to focus research on long-term health effects in vulnerable populations "like adolescents and young adults," signaling precautionary concern about potential harms alongside the reform agenda
The order notes that THC levels in hemp-derived cannabinoid products can affect both pain treatment efficacy and adverse events, and that some full-spectrum CBD products will be reclassified as controlled substances under Public Law 119-37 due to THC content, framing the CBD landscape as one of genuine safety complexity rather than straightforward consumer benefit

Neutral/technical elements

The order defines the distinction between Schedule I and Schedule III classifications under the CSA in factual, statutory terms
The order references the pending administrative law hearing on the May 2024 DOJ proposed rulemaking without characterizing its outcome
The order cites 7 U.S.C. 1639o for the statutory definition of hemp-derived cannabinoid products
The order notes that section 781 of Public Law 119-37 will reclassify certain full-spectrum CBD products as controlled substances upon taking effect, presenting this as a legal complexity rather than a policy judgment
Section 3 contains standard general provisions language disclaiming the creation of enforceable rights and conditioning implementation on appropriations availability

Context for sentiment claims

The order provides specific sourcing for several major assertions: the 2023 FDA review, the HHS recommendation to DEA, the NIDA concurrence, and the May 2024 DOJ proposed rule are all cited by agency and date
Statistical claims (1 in 4 adults with chronic pain, 6 in 10 medical marijuana users citing pain management, 20 percent of veterans reporting reduced opioid use) are attributed to research surveys but specific studies are not named or cited by publication
The claim that "more than 30,000 licensed healthcare practitioners" recommend marijuana across 43 jurisdictions is attributed to the HHS Office of the Assistant Secretary of Health
The claim regarding inaccurate CBD product labeling is attributed to "a recent study" without further identification
The order does not provide citations for claims about seniors' health-related quality of life improvements or CBD use prevalence figures

3) SECTION-BY-SECTION SENTIMENT PROGRESSION‌‍⁠

Section 1 — Purpose and Policy

Dominant sentiment: Reformist and critical of prior federal inaction, grounded in patient-welfare framing, but with a concurrent precautionary strand focused on research gaps and population-level risks
Key phrases: "decades of Federal drug control policy have neglected"; "does not serve the Americans"; "long-term health effects in vulnerable populations like adolescents and young adults"
Why this matters: The order establishes the rhetorical foundation for urgency by characterizing the status quo as a failure, which directly justifies the directive actions in Section 2. However, the simultaneous emphasis on safety risks, labeling failures, and vulnerable populations signals that the order's sentiment is not simply pro-access—it is also risk-conscious in ways that shape the research and regulatory mandates that follow

Section 2 — Rescheduling Medical Marijuana and Improving Access to Cannabidiol Products

Dominant sentiment: Directive and procedurally confident, framing agency action as straightforward execution of already-established recommendations
Key phrases: "most expeditious manner"; "allow Americans to benefit from access"
Why this matters: The order's language of urgency ("most expeditious manner") signals prioritization of rescheduling completion while delegating CBD regulatory framework development to a multi-agency process, reflecting the relative legal complexity of each track. The research mandate in Section 2(b) is the order's stated mechanism for closing the gap between current use and medical knowledge—distinct from the rescheduling directive in Section 2(a)

Section 3 — General Provisions

Dominant sentiment: Legally neutral and protective of existing institutional authority
Key phrases: No rhetorically significant phrases; standard boilerplate language throughout
Why this matters: The standard disclaimers preserve agency authority and limit judicial enforceability, which is consistent with the order's reliance on existing rulemaking processes rather than unilateral executive action

4) ANALYTICAL DISCUSSION‌‍⁠

Alignment‌‍⁠ of sentiment with substantive goals: The order's rhetorical strategy closely tracks its policy objectives. By leading with patient populations—veterans, seniors, chronic pain sufferers—the order frames rescheduling as a humanitarian correction rather than a drug liberalization measure. This framing is consistent with the substantive ask: not legalization, but movement from Schedule I to Schedule III, a distinction the order takes care to explain in clinical terms. The negative sentiment directed at prior federal policy is calibrated to justify urgency without characterizing the rescheduling as a novel or controversial act; instead, the order repeatedly emphasizes that HHS, FDA, NIDA, and DOJ have already moved in this direction, positioning the executive order as an accelerant of existing bureaucratic momentum rather than a policy reversal. Critically, the order's reformist sentiment is paired with a precautionary counterweight: the explicit focus on long-term health effects in adolescents and young adults, and the detailed enumeration of CBD safety and labeling risks, ensures the document cannot be read as straightforwardly pro-access. The research mandate is framed as the mechanism for resolving this tension—closing the gap between use and knowledge—rather than the rescheduling directive itself.

Potential impacts on relevant stakeholders: The order's framing has differential implications for identifiable groups. Patients and healthcare providers are positioned as primary beneficiaries of the stated research and regulatory clarity goals. The pharmaceutical and hemp industries are implicated by the CBD regulatory framework development mandate, though the order's language is neutral on commercial interests. State-level medical marijuana programs are acknowledged as a legitimizing data point—the order states that 40 states plus D.C. have sanctioned programs—but the order does not address the federal-state legal tension directly. Administrative law judges and DEA rulemaking processes are implicated by the Section 2(a) directive to complete rescheduling "in the most expeditious manner," language that could be read as applying political pressure to an ongoing quasi-judicial proceeding, though the order explicitly conditions action on compliance with 21 U.S.C. 811.

Comparison to typical executive order language: This order is more data-intensive in its preamble than is typical for executive orders, which more commonly rely on broad policy assertions without statistical scaffolding. The inclusion of specific agency findings, patient survey figures, and statutory cross-references gives Section 1 a character closer to a regulatory preamble or legislative finding than standard executive order purpose language. The directive provisions in Section 2 are, by contrast, relatively brief and procedurally conventional. The order also notably avoids the adversarial or crisis-framing language common in executive orders that target prior administration policies; the critique of "decades of Federal drug control policy" is attributed to systemic neglect rather than to specific prior administrations, which moderates the partisan register of the document.

Character as a political transition document and analytical limitations: The order functions partly as a political transition document, signaling a new administration's alignment with a policy direction that had been initiated under a prior administration (the 2023 HHS recommendation and 2024 DOJ proposed rule both predate this order). This creates an analytical complexity: the order's negative framing of prior federal inaction implicitly encompasses multiple administrations of both parties, which diffuses rather than concentrates political attribution. A limitation of this sentiment analysis is that it cannot assess the gap between the order's stated intentions and likely implementation outcomes—particularly given that the rescheduling rulemaking remains subject to an administrative law hearing process that the order cannot unilaterally conclude. Additionally, the order's statistical claims, while presented as evidence, are drawn from surveys and studies of varying methodological rigor; this analysis treats them as rhetorical elements rather than independently verified facts, which is the appropriate scope for a sentiment analysis of the document's language rather than its underlying empirical claims.